Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies
<b>Background/Objectives</b>: <sup>123</sup>Iodo-metaiodobenzylguanidine single photon emission computed tomography/computed tomography (<sup>123</sup>I-MIBG SPECT/CT) is used to evaluate the cardiac sympathetic nervous system in cardiac diseases such as arrhythmo...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/1/24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841549286534283264 |
|---|---|
| author | Johannes M. Hagen Maximilian Scheifele Mathias J. Zacherl Sabrina Katzdobler Alexander Bernhardt Matthias Brendel Johannes Levin Günter U. Höglinger Sebastian Clauß Stefan Kääb Andrei Todica Guido Boening Maximilian Fischer |
| author_facet | Johannes M. Hagen Maximilian Scheifele Mathias J. Zacherl Sabrina Katzdobler Alexander Bernhardt Matthias Brendel Johannes Levin Günter U. Höglinger Sebastian Clauß Stefan Kääb Andrei Todica Guido Boening Maximilian Fischer |
| author_sort | Johannes M. Hagen |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: <sup>123</sup>Iodo-metaiodobenzylguanidine single photon emission computed tomography/computed tomography (<sup>123</sup>I-MIBG SPECT/CT) is used to evaluate the cardiac sympathetic nervous system in cardiac diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and α-synucleinopathies such as Parkinson’s diseases. A common feature of these diseases is denervation. We aimed to compare quantitative and semi-quantitative cardiac sympathetic innervation using <sup>123</sup>I-MIBG imaging of ARVC and α-synucleinopathies. <b>Methods</b>: Cardiac innervation was assessed using <sup>123</sup>I-MIBG SPECT/CT in 20 patients diagnosed with definite ARVC and 8 patients with clinically diagnosed α-synucleinopathies. Heart-to-mediastinum-ratio (H/M-ratio), as semi-quantitative, was evaluated. Additionally, standardized uptake value (SUV), as quantitative, was measured as SUV<sub>median</sub>, SUV<sub>max</sub>, and SUV<sub>peak</sub> in the left ventricle (LV), the right ventricle (RV), and in the global heart, based on a CT scan following quantitative image reconstruction. <b>Results</b>: The quantification of <sup>123</sup>I-MIBG uptake in the LV, the RV, and the global heart was feasible in patients suffering from α-synucleinopathies. SUV<sub>median</sub>, and SUV<sub>peak</sub> demonstrated a significant difference between ARVC and α-synucleinopathies across all regions, with the α-synucleinopathy group showing a lower uptake. In addition, the H/M ratio showed significantly lower uptake in patients with α-synucleinopathies than in patients with ARVC. <b>Conclusions</b>: Patients with α-synucleinopathies demonstrate significantly lower cardiac innervation in semi-quantitative and quantitative examinations than ARVC patients. The comparison of semi-quantitative and quantitative examinations suggests that quantitative examination offers an advantage. Quantitative analysis can be performed separately for the LV, RV, and global heart. However, analyzing the LV or RV does not provide additional benefit over analyzing the global heart in distinguishing between α-synucleinopathies and ARVC. Considering the different clinical manifestations of these two diseases, the absolute SUV values should not be generalized across different pathologies, and disease-specific ranges should be used instead. |
| format | Article |
| id | doaj-art-953bef1ecacd4347b2767bc239361ad9 |
| institution | Kabale University |
| issn | 2075-4418 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-953bef1ecacd4347b2767bc239361ad92025-01-10T13:16:29ZengMDPI AGDiagnostics2075-44182024-12-011512410.3390/diagnostics15010024Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-SynucleinopathiesJohannes M. Hagen0Maximilian Scheifele1Mathias J. Zacherl2Sabrina Katzdobler3Alexander Bernhardt4Matthias Brendel5Johannes Levin6Günter U. Höglinger7Sebastian Clauß8Stefan Kääb9Andrei Todica10Guido Boening11Maximilian Fischer12Department of Nuclear Medicine, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Neurology, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Neurology, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Neurology, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Neurology, Ludwig-Maximilians-University, 81377 Munich, GermanyInterfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU Munich, 81377 Munich, GermanyInterfaculty Center for Endocrine and Cardiovascular Disease Network Modelling and Clinical Transfer (ICONLMU), LMU Munich, 81377 Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians-University, 81377 Munich, GermanyDepartment of Medicine I, University Hospital Munich, Ludwig-Maximilians-University, 81377 Munich, Germany<b>Background/Objectives</b>: <sup>123</sup>Iodo-metaiodobenzylguanidine single photon emission computed tomography/computed tomography (<sup>123</sup>I-MIBG SPECT/CT) is used to evaluate the cardiac sympathetic nervous system in cardiac diseases such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and α-synucleinopathies such as Parkinson’s diseases. A common feature of these diseases is denervation. We aimed to compare quantitative and semi-quantitative cardiac sympathetic innervation using <sup>123</sup>I-MIBG imaging of ARVC and α-synucleinopathies. <b>Methods</b>: Cardiac innervation was assessed using <sup>123</sup>I-MIBG SPECT/CT in 20 patients diagnosed with definite ARVC and 8 patients with clinically diagnosed α-synucleinopathies. Heart-to-mediastinum-ratio (H/M-ratio), as semi-quantitative, was evaluated. Additionally, standardized uptake value (SUV), as quantitative, was measured as SUV<sub>median</sub>, SUV<sub>max</sub>, and SUV<sub>peak</sub> in the left ventricle (LV), the right ventricle (RV), and in the global heart, based on a CT scan following quantitative image reconstruction. <b>Results</b>: The quantification of <sup>123</sup>I-MIBG uptake in the LV, the RV, and the global heart was feasible in patients suffering from α-synucleinopathies. SUV<sub>median</sub>, and SUV<sub>peak</sub> demonstrated a significant difference between ARVC and α-synucleinopathies across all regions, with the α-synucleinopathy group showing a lower uptake. In addition, the H/M ratio showed significantly lower uptake in patients with α-synucleinopathies than in patients with ARVC. <b>Conclusions</b>: Patients with α-synucleinopathies demonstrate significantly lower cardiac innervation in semi-quantitative and quantitative examinations than ARVC patients. The comparison of semi-quantitative and quantitative examinations suggests that quantitative examination offers an advantage. Quantitative analysis can be performed separately for the LV, RV, and global heart. However, analyzing the LV or RV does not provide additional benefit over analyzing the global heart in distinguishing between α-synucleinopathies and ARVC. Considering the different clinical manifestations of these two diseases, the absolute SUV values should not be generalized across different pathologies, and disease-specific ranges should be used instead.https://www.mdpi.com/2075-4418/15/1/24ARVCα-synucleinopathies<sup>123</sup>I-MIBGSUVheartRV |
| spellingShingle | Johannes M. Hagen Maximilian Scheifele Mathias J. Zacherl Sabrina Katzdobler Alexander Bernhardt Matthias Brendel Johannes Levin Günter U. Höglinger Sebastian Clauß Stefan Kääb Andrei Todica Guido Boening Maximilian Fischer Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies Diagnostics ARVC α-synucleinopathies <sup>123</sup>I-MIBG SUV heart RV |
| title | Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies |
| title_full | Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies |
| title_fullStr | Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies |
| title_full_unstemmed | Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies |
| title_short | Diagnostic Efficacy of <sup>123</sup>Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies |
| title_sort | diagnostic efficacy of sup 123 sup iodo metaiodobenzylguanidine spect ct in cardiac vs neurological diseases a comparative study of arrhythmogenic right ventricular cardiomyopathy and α synucleinopathies |
| topic | ARVC α-synucleinopathies <sup>123</sup>I-MIBG SUV heart RV |
| url | https://www.mdpi.com/2075-4418/15/1/24 |
| work_keys_str_mv | AT johannesmhagen diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT maximilianscheifele diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT mathiasjzacherl diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT sabrinakatzdobler diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT alexanderbernhardt diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT matthiasbrendel diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT johanneslevin diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT gunteruhoglinger diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT sebastianclauß diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT stefankaab diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT andreitodica diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT guidoboening diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies AT maximilianfischer diagnosticefficacyofsup123supiodometaiodobenzylguanidinespectctincardiacvsneurologicaldiseasesacomparativestudyofarrhythmogenicrightventricularcardiomyopathyandasynucleinopathies |